ACTR-78. TAMIGA: A PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF CONTINUOUS BEVACIZUMAB THROUGH MULTIPLE LINES OF TREATMENT FOR GLIOBLASTOMA

Bevacizumab (anti-vascular endothelial growth factor) prolongs progression-free survival (PFS) in newly diagnosed and recurrent glioblastoma. We hypothesized overall-survival (OS) benefit from continuing bevacizumab (BEV) through multiple lines of treatment (TML). Patients with newly diagnosed gliob...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Brandes, Alba, Gil, Miquel Gil, Saran, Frank, Carpentier, Antoine F, Nowak, Anna, Mason, Warren, Dubois, Francois, Finocchiaro, Gaetano, Fountzilas, George, Zagonel, Vittorina, Cernea, Dana M, Chinot, Olivier, Makrutzki, Martina, Mpofu, Chiedzo, Urban, Hans-Joerg, Pichler, Josef
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2017
Konular:
Abstracts
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693008/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.065
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller